Prostate Cancer | Specialty

The OncLive Prostate Cancer condition center page is a comprehensive resource for clinical news and expert insights on how to approach treatment for patients with nonmetastatic, castration-resistant, or castration-sensitive prostate cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, ongoing research, and treatment advances with androgen receptor inhibitors, PARP inhibitors, and more in prostate cancer.

Dr. Ryan on Neoadjuvant Abiraterone Acetate

July 11th 2012

Dr. Charles Ryan from the UCSF Helen Diller Family Comprehensive Cancer Center Discusses Neoadjuvant Abiraterone Acetate

Marital Status Impacts Survival in Prostate Cancer Patients

July 11th 2012

Marital status is an independent predictor of disease-related mortality and overall mortality in men with prostate cancer.

Dr. Fong Discusses Immune Response to Sipuleucel-T

July 10th 2012

Dr. Lawrence Fong from University of California, San Francisco, Discusses Immune Response to Sipuleucel-T

Vitamin D Might Benefit Patients With Prostate Cancer

July 5th 2012

The cancer proliferation marker Ki-67 decreased significantly in men who took high-dose vitamin D in the weeks leading up to radical prostatectomy for localized prostate cancer.

Case-Based Discussion: Sequencing Prostate Cancer Therapy

July 3rd 2012

Case-based discussion on sequencing prostate cancer therapies for a 72-year-old man with a metastatic adenocarcinoma with small-cell components, a PSA score of 80, and a Gleason score of 10.

Dr. Shore on the Enzalutamide Mechanism of Action

June 28th 2012

Neal D. Shore, MD, Managing Partner, Atlantic Urology Clinics, Director, CPI, Carolina Urologic Research Center, discusses enzalutamide, a well tolerated oral therapy.

High Points and Hurdles: Immunotherapy Moves Forward

June 27th 2012

Immunotherapy is maintaining its momentum in clinical development programs, with explorations under way in many tumor types, including breast and lung cancers previously considered poor candidates for such modalities.

Dr. Taplin on Neoadjuvant ADT Plus Hormonal Therapy

June 25th 2012

Dr. Mary-Ellen Taplin, from the Dana-Farber Cancer Institute, on Neoadjuvant ADT Plus Hormonal Therapy for Prostate Cancer.

Affirming the Promise of Enzalutamide: A New Opportunity for Integrative Care in Prostate Cancer

June 25th 2012

Enzalutamide seems poised to become an exciting addition to the growing list of novel therapies approved for the treatment of prostate cancer.

Novel Concepts Include New Agents, Combinations

June 19th 2012

Oncology specialists who treat patients with mCRPC can look forward to choosing from an expanding array of therapeutic tools, including regimens.

Dr. Ryan Discusses Sequencing Prostate Cancer Therapies

June 18th 2012

Dr. Charles Ryan, from UCSF Helen Diller Family Comprehensive Cancer Center, Discusses Sequencing Castration-Resistant Prostate Cancer Therapies.

Four Later-Stage Immunotherapy Strategies Appear Promising

June 14th 2012

While many approaches to using immunotherapy for the treatment of prostate cancer are under study, four strategies currently in later-stage clinical development have emerged as the most promising.

Studies Crystallize Variable Impact of ADT-RT Combination Therapy

June 13th 2012

The results of several long-term clinical trials published last year clarify the role of combination ADT and RT in the treatment of men with prostate cancer.

IPCC Case-Based Discussion: How Should We Sequence Therapy?

June 12th 2012

Three case studies focused on how best to sequence therapy in prostate cancer were presented by Daniel P. Petrylak, MD, and discussed by a panel that included Robert Dreicer, MD, and Oliver Sartor, MD.

Dr. Ryan on the COU-AA-302 Interim Analysis Results

June 11th 2012

Dr. Charles Ryan, from the UCSF Diller Family Comprehensive Cancer Center, on the COU-AA-302 Abiraterone Acetate Interim Analysis Results.

Dr. Shore Discusses the Enzalutamide AFFIRM Trial

June 8th 2012

Dr. Neal Shore, from the Atlantic Urology Clinics, Discusses the Enzalutamide (MDV3100) AFFIRM Trial

Dr. Taplin on Neoadjuvant Abiraterone and Leuprolide

June 8th 2012

Dr. Mary-Ellen Taplin, from Dana-Farber Cancer Institute, on Neoadjuvant Abiraterone Acetate and Leuprolide Acetate

With Continuous Hormonal Therapy, Certain Men With Prostate Cancer Get Marked Boost in Survival

June 3rd 2012

Patients with metastatic, hormone-sensitive prostate cancer and minimal disease spread experience a two-year boost in median survival when treated with continuous, rather than intermittent, hormonal therapy.

Dr. Concepcion Discusses Prostate Cancer Therapies

May 31st 2012

Dr. Raoul Concepcion, from Urology Associates, PC, Nashville, TN, Discusses New Prostate Cancer Therapies.

Dr. Gomella on the Unique Attributes of Neoadjuvant Zytiga

May 30th 2012

Dr. Leonard Gomella, from Jefferson Kimmel Cancer Center, on the Unique Attributes of Neoadjuvant Zytiga.